成人Ph染色体阴性急性淋巴细胞白血病的治疗进展

doi:10.3969/j.issn.1674-490X.2019.04.005

医学研究与教育 ›› 2019, Vol. 36 ›› Issue (4): 24-29.DOI: 10.3969/j.issn.1674-490X.2019.04.005

成人Ph染色体阴性急性淋巴细胞白血病的治疗进展

庞艳彬¹,杨会彬²,范丽霞¹,薛华¹,化罗明¹

1.河北大学附属医院血液内科, 河北保定 071000;
2.河北大学附属医院放疗科, 河北保定 071000

收稿日期:2019-01-04 出版日期:2019-08-25 发布日期:2019-08-25
通讯作者: 化罗明(1965—),男,河北保定人,主任医师,教授,硕士,硕士生导师,主要从事血液病耐药机制的研究。E-mail: 820177315@qq.com
作者简介:庞艳彬(1980—),男,河北蠡县人,主治医师,硕士,主要从事血液病耐药机制的研究。
基金资助:
保定市科学技术研究与发展指导计划项目(17ZF263);河北大学附属医院青年科研基金项目(2017Q014)

Received:2019-01-04 Online:2019-08-25 Published:2019-08-25

摘要/Abstract

摘要： 虽然成人Ph染色体阴性的急性淋巴细胞(Ph-ALL)的治疗效果落后于儿童急性淋巴细胞白血病,但是随着对ALL生物学特点认识的进展治疗效果也取得进展,与儿童ALL疗效差距正在逐渐缩小。在青少年和年轻成人急性淋巴细胞白血病患者中采用儿童化疗方案、根据患者的遗传学特点和微小残留病变进行危险性分层并调整缓解后治疗进一步提高了患者的治疗效果。近年来,以单克隆抗体为基础的免疫治疗在成人Ph-ALL的治疗中取得初步成功。现将近年来Ph-ALL的治疗进展做一简要总结。

关键词: 急性淋巴细胞白血病, 微小残留病变, Ph染色体, 单克隆抗体

Abstract: Although the therapeutic effect of adult Ph chromosome negative acute lymphocyte(Ph-ALL)is lagging behind that of childhood acute lymphoblastic leukemia, the gap is gradually narrowing with the progress of understanding the biological characteristics of ALL, which is transforming the progress of therapeutic effect. In adolescents and young adults with acute lymphoblastic leukemia adapted from pediatric protocols,risk stratification based on genetic characteristics and minimal residual disease, and adjustment of post-remission treatment further improve the therapeutic effect of patients. In recent years, immunotherapy based on monoclonal antibodies has achieved initial success in the treatment of adult Ph-ALL. In this paper, the recent developments on the treatment of Ph-ALL is briefly summarized.

Key words: acute lymphoblastic leukemia, minimal residual disease, Ph chromosome, monoclonal antibodies

中图分类号:

庞艳彬,杨会彬,范丽霞,薛华,化罗明. 成人Ph染色体阴性急性淋巴细胞白血病的治疗进展[J]. 医学研究与教育, 2019, 36(4): 24-29.

参考文献

[1] PARIKH S A, LITZOW M R. Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development[J]. Future Oncol, 2014, 10(14): 2201-2212. DOI: 10.2217/fon.14.81.
[2] FREY N V, LUGER S M. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia[J]. Blood, 2015, 126(5):589-596. DOI: 10.1182/blood-2014-09-551937.
[3] ALDOSS I, STEIN A S. Advances in adult acute lymphoblastic leukemia therapy[J]. Leuk Lymphoma, 2018, 59(5):1033-1050. DOI: 10.1080/10428194.2017.1354372.
[4] HUGUET F, CHEVRET S, LEGUAY T, et al. Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial[J]. J Clin Oncol, 2018, 36(24): 2514-2523. DOI: 10.1200/JCO.2017.76.8192.
[5] ISSA G C, KANTARJIAN H M, YIN C C, et al. Prognostic impact of pretreatment cytogenetics in adult philadelphia chromosome-negative acute lymphoblastic eukemia in the era of minimal residual disease[J]. Cancer,2017, 123(3): 459-467. DOI: 10.1002/cncr.30376.
[6] ISSHIKI Y, OHWADA C, SAKAIDA E, et al. CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatricinspired chemotherapy[J]. Jpn J Clin Oncol, 2017, 47(11): 1047-1054. DOI: 10.1093/jjco/hyx126.
[7] SHORT NJ, KANTARJIAN H M, SASAKI K, et al. Prognostic significance of day 14 bone marrow evaluation in adults with philadelphia chromosome-negative acute lymphoblastic leukemia[J]. Cancer, 2016, 122(24): 3812-3820. DOI: 10.1002/cncr.30262.
[8] KUMAR A J, GIMOTTY P A, GELFAND J M, et al. Delays in post-remission chemotherapy for philadelphia chromosome negative acute lymphoblastic leukemia are associated with Inferior outcomes in patients who undergo allogeneic transplant: an analysis from ECOG 2993/MRC UK ALLXII[J]. Am J Hematol, 2016, 91(11): 1107-1112. DOI: 10.1002/ajh.24497.
[9] MAURY S, CHEVRETT S, THOMAS X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia[J]. N Engl J Med, 2016, 375(11): 1044-1053. DOI: 10.1056/NEJMoa1605085.
[10] TVITO A, ROWE J M. Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia[J]. Expert Opin Biol Ther, 2017, 17(12): 1557-1564. DOI: 0.1080/14712598.2017.1387244.
[11] JABBOUR E, RAVANDI F, KEBRIAEI P, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory philadelphia chromosome-negative acute lymphoblastic leukemialA Phase 2 clinical trial[J]. JAMA Oncol, 2018, 4(2): 230-234. DOI: 10.1001/jamaoncol.2017.2380.
[12] WOLACH O, STONE R M. Blinatumomab for the treatment of philadelphia chromosome-negative, precursor B-cell acute lymphoblastic leukemia[J]. Clin Cancer Res,2015, 21(19): 4262-4269. DOI: 10.1158/1078-0432.CCR-15-0125.
[13] SCHILLER G J, DAMON L E, COUTRE S E, et al. High-dose vincristine sulfate liposome injection, for advanced, relapsed, or refractory philadelphia chromosome-negative acute lymphoblastic aeukemia in an adolescent and young adult subgroup of a phase 2 clinical trial[J]. J Adolesc Young Adult Oncol, 2018, 7(5): 546-552. DOI: 10.1089/jayao.2018.0041.
[14] JABBOUR E, PUI C H, KANTARJIAN H. Progress and innovations in the management of adult acute lymphoblastic leukemia[J]. JAMA Oncol, 2018, 4(10):1413-1420. DOI: 10.1001/jamaoncol.
[15] SAKURA T, HAYAKAWA F, SUGIURA I, et al. High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG[J]. Leukemia, 2018, 32(3): 626-632. DOI: 10.1038/leu.2017.283.
[16] TASIAN S K, Loh M L, Hunger S P. Philadelphia chromosome-like acute lymphoblastic leukemia[J].Blood, 2017, 130(19): 2064-2072. DOI: 10.1182/blood-2017-06-743252.
[17] ARBER D A, ORAZI A, HASSERJIAN R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 27(20): 2391-2405. DOI: 10.1182/blood-2016-03-643544.
[18] TERWILLIGER T, ABDUL-HAY M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update[J]. Blood Cancer J, 2017, 7(6): e577. DOI: 10.1038/bcj.2017.53.
[19] JAIME-PEREZ J C, COLUNGA-PEDRAZA P R, GUTIERREZ-AGUIRRE C H, et al. Efficacy of mitoxantrone as frontline anthracycline during induction therapy in adults with newly diagnosed acute lymphoblastic leukemia. A single-center experience[J]. Leuk Lymphoma, 2015, 56(9): 2524-2528. DOI: 10.3109/10428194.2015.1009058.
[20] KOPRIVNIKAR J, MCCLOKEY J, FADERL S. Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia[J].Onco Targets Ther, 2017, 10: 1413-1422. DOI: 10.2147/OTT.S106810.
[21] 季静,韩颖,化罗明,等. 大剂量甲氨蝶呤化疗副作用观察及处置[J]. 医学研究与教育, 2012, 29(6): 32-34. DOI: 1674-490X(2012)06-0032-03.
[22] SEFTEL M D, NEUBERG D, ZHANG M J, et al.Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission[J]. Am J Hematol,2016, 91(3): 322-329. DOI: 10.1002/ajh.24285.
[23] TOPP M S, GÖKBUGET N, STEIN A S, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study[J]. Lancet Oncol, 2015, 16(1): 57-66. DOI: 10.1016/S1470-2045(14)71170-2.
[24] FLOWERS C R, RAMSEY S D.What can cost-effectiveness analysis tell us about chimeric antigen receptor T-Cell therapy for relapsed acute lymphoblastic leukemia? [J]. J Clin Oncol, 2018, 36(32): 3183-3185. DOI: 10.1200/JCO.2018.79.3570.
[25] MAUDE S L, LAETSCH T W, BUECHNER J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5): 439-448. DOI: 10.1200/JCO.2018.79.3570.
[26] FREY N V. CAR T cells for acute lymphoblastic leukemia[J]. Am J Hematol,2019, 94(S1): S24-S27. DOI: 10.1002/ajh.25442.

成人Ph染色体阴性急性淋巴细胞白血病的治疗进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价

[1]	李文艳,杨宏莉,杨静,耿坤静. her2基因在肺癌中的研究进展[J]. 医学研究与教育, 2010, 27(4): 83-86.
[2]	郭明,薛华,李春燕,赵松颖,范丽霞,王静,季静. VAD-ASP方案治疗复发难治性成人急性淋巴细胞白血病[J]. 医学研究与教育, 2009, 26(5): 24-25.